Status:
COMPLETED
Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis
Lead Sponsor:
AbbVie
Conditions:
Arthritis, Juvenile Rheumatoid
Eligibility:
All Genders
Up to 99 years
Brief Summary
This study of Humira will be conducted to clarify the following with regard to the treatment of juvenile idiopathic arthritis affecting multiple joints with this drug: * Unknown adverse drug reaction...
Eligibility Criteria
Inclusion
- All patients with Juvenile idiopathic arthritis who are not responding well to conventional therapy and receive Humira will be enrolled in the survey
Exclusion
- Contraindications according to the Package Insert
- Patients who have serious infections
- Patients who have tuberculosis
- Patients with a history of hypersensitivity to any ingredient of Humira
- Patients who have demyelinating disease or with a history of demyelinating disease
- Patients who have congestive cardiac failure
Key Trial Info
Start Date :
July 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 2 2018
Estimated Enrollment :
375 Patients enrolled
Trial Details
Trial ID
NCT01412021
Start Date
July 1 2011
End Date
April 2 2018
Last Update
August 8 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.